Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Shares Outstanding (2018 - 2025)

10x Genomics' Shares Outstanding history spans 8 years, with the latest figure at $127.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 4.42% year-over-year to $127.7 million; the TTM value through Dec 2025 reached $127.7 million, up 4.42%, while the annual FY2025 figure was $127.7 million, 4.42% up from the prior year.
  • Shares Outstanding for Q4 2025 was $127.7 million at 10x Genomics, up from $126.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $127.7 million in Q4 2025 and bottomed at $109.6 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $117.8 million (2023), against an average of $117.9 million.
  • The largest annual shift saw Shares Outstanding increased 11.66% in 2021 before it grew 2.38% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $112.5 million in 2021, then grew by 2.38% to $115.2 million in 2022, then rose by 3.39% to $119.1 million in 2023, then grew by 2.68% to $122.3 million in 2024, then increased by 4.42% to $127.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Shares Outstanding are $127.7 million (Q4 2025), $126.5 million (Q3 2025), and $124.4 million (Q2 2025).